spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Acute Myeloid Leukemia 

 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Aug 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Mar 2022
TC BioPharm Announces FDA Orphan Drug Status Granted for OmnImmune(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2022
TC Biopharm Announces Appointment of New Board Members
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Nov 2021
Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 20 May 2021
BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Dec 2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Dec 2020
Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2020
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
Biopharmaceutical Personnel
 HSMN NewsFeed - 12 Oct 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jun 2020
Cardiff Oncology Secures $13.5 Million Equity Investment from Biotech-Focused Fundamental Institutional Investors Acorn Bioventures and CAM Capital
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Apr 2020
Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing
Biopharmaceuticals
 HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Dec 2019
Fluxion Launches Three New Spotlight(TM) Liquid Biopsy NGS Panels
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2019
BioAtla Appoints Eric Sievers, M.D., As Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jan 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2018
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Sep 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2018
Cantex Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CX-01 For The Treatment Of Patients Over Age 60 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Aug 2018
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Jul 2018
MEI Pharma Promotes David M. Urso to Chief Operating Office
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Apr 2018
Forty Seven Inc. Appoints Ian T. Clark to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Apr 2018
SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Feb 2018
Trethera Corporation Announces FDA Clearance of Investigational New Drug Application for TRE-515
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Dec 2017
Merus Announces the U.S. Court of Appeals for the Federal Circuit Denies Regeneron's Petition to Rehear the Panel's Decision Affirming Merus' Inequitable Conduct Claim Against Regeneron
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 6 Dec 2017
Forty Seven Inc. Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Sep 2017
FDA approves Mylotarg for treatment of acute myeloid leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Jul 2017
Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
Regenerative Medicine Neurology
 HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 May 2017
New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
Regenerative Medicine Neurosurgery
 HSMN NewsFeed - 28 Apr 2017
Invivoscribe(R) Receives FDA Approval for the LeukoStrat(R) CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt(R) and is the First Companion Diagnostic for AML
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Apr 2017
Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2017
MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2017
Moleculin Receives Orphan Drug Designation for Annamycin for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2017
Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel
 HSMN NewsFeed - 19 Oct 2016
SELLAS(TM) Life Sciences Appoints Former Barclays Biotechnology Research Analyst as Chief Business and Strategy Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2016
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox(R) for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Sep 2016
Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2016
Celator Pharmaceuticals(R) Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS(TM) (CPX-351) Significantly Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 25 Apr 2016
Celator(R) Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOS(TM) Compared to Standard Treatment for Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 28 Jan 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 24 Aug 2015
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Aug 2015
Cantex Pharmaceuticals Enhances Executive Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Aug 2015
Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Apr 2015
MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Sep 2014
Celator(R) Pharmaceuticals Announces Appointment of Michael Dougherty as Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Aug 2014
Karyopharm Appoints Justin Renz Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2014
OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Apr 2014
Actinium Announces Key Additions to Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Apr 2014
MEI Pharma Adds Former VC David Urso as Senior Vice President of Corporate Development and General Counsel
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Mar 2014
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2014
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2014
Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2013
Celator(R) Pharmaceuticals Appoints Joseph M. Lobacki to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Dec 2013
Lorus Therapeutics Completes New Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Nov 2013
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine in AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 16 Sep 2013
Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2013
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jul 2013
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 24 Apr 2013
Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2013
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2013
Acceleron Receives Two FDA Orphan Designations for ACE-536
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 30 Jan 2013
MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jan 2013
Celator(R) Pharmaceuticals Announces Appointment of Lisa DeLuca as Vice President, Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2012
Celator(R) Pharmaceuticals Announces Appointment of Fred Powell as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Oct 2012
Sunesis Pharmaceuticals Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Sep 2012
Actinium Pharmaceuticals Announces New Round of Financing
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2012
Third Critically Ill Patient Successfully Treated With Pluristem's PLX Cells Under Compassionate Use
Regenerative Medicine Oncology
 HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Aug 2012
Genmab Enters Worldwide Agreement With Janssen for Daratumumab
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Aug 2012
Actinium Pharmaceuticals Strengthens Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2012
Formula Pharmaceuticals Appoints Morton Collins to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 May 2012
Dr. Carlo Croce joins Trovagene as Scientific Consultant and Member of the Company's Scientific Advisory Board
Diagnostics Personnel
 HSMN NewsFeed - 25 Apr 2012
Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2012
Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
Diagnostics Personnel
 HSMN NewsFeed - 15 Mar 2012
TetraLogic Pharmaceuticals Appoints C. Glenn Begley as Senior Vice President Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Feb 2012
Stephen Zaniboni Joins Trovagene, Inc. as Chief Financial Officer
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Dec 2011
Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2011
Abbott's Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
Diagnostics FDA
 HSMN NewsFeed - 3 Oct 2011
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2011
TrovaGene, Inc., Announces Worldwide Exclusive Licensing of Assay for Hairy Cell Leukemia
Diagnostics Licensing Oncology
 HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2011
Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2011
Sunesis Receives FDA Fast Track Designation for Vosaroxin in AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2011
Optimer Pharmaceuticals Announces Key Additions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2011
Celator(R) Pharmaceuticals and Cephalon, Inc. Agree to Extend Research Agreement into Next Phase of Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2010
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Sep 2010
Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Sep 2010
Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Jul 2010
EpiCept Amends Employment Agreement and Completes Severance Agreements with Executive Officers
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2010
EpiCept Corporation Names Rita Kelley Senior Director of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jun 2010
Eisai Announces Results of Phase III Study of Dacogen(R) (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2010
EntreMed Receives Orphan Drug Designation for ENMD-2076 in Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2010
Meda In-Licenses Exclusive Rights To Ceplene
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Dec 2009
Vion Pharmaceuticals Announces FDA Conclusion
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Nov 2009
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2009
APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Oct 2008
Cancer Drug Vidaza(R) Receives Positive Opinion from European Regulatory Authority for Treatment of MDS and AML
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jul 2008
Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 23 Jun 2008
Lorus Therapeutics announces that the European Medicines Agency (EMEA) has granted the orphan drug designation to LOR-2040 for the treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jun 2008
Study of VIDAZA(R) in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2008
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2008
EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jan 2008
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2007
Antisoma opens US Headquarters in Princeton, New Jersey
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
Ambit Biosciences Raises Over $49 Million in Series D Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Oct 2007
European Commission Grants Orphan Drug Designation to Xanthus' Xanafide for the Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2007
EpiCept Reports Regulatory Progress on Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2007
Xenomics Announces Agreement with Ipsogen for Diagnostic Assays of Leukemia
Diagnostics Oncology Licensing
 HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2007
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2007
Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Diagnostics Oncology
 HSMN NewsFeed - 23 Jul 2007
EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2007
EpiCept Establishes Direct Licensing Agreement with Dalhousie University for EpiCept(TM) NP-1
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jun 2007
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Jun 2007
NanoMed Pharmaceuticals Hires Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2007
Lorus Therapeutics announces the initiation of a clinical trial of GTI-2040 in acute leukemia and myelodysplastic syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2007
Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jun 2007
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2007
EpiCept Initiates Two Phase IIb Trials with NP-1
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
EpiCept Corporation Appoints Stephane Allard, M.D. as New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Mar 2007
Stemline Therapeutics In-Licenses Phase I Oncology Compound
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Feb 2007
Clinical Data Supporting Development of ChemGenex's Ceflatonin(R) in Imatinib-Resistant CML Published in Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2007
Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2007
Bioenvision Files with EMeA for Label Extension of Evoltra(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2007
Xanthus Receives Orphan Drug Designation of Xanafide for the Treatment Of AML
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jan 2007
Ambit Biosciences Appoints Wendell Wierenga, Ph.D., as Executive Vice President of Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Jan 2007
Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Dec 2006
EpiCept Licenses Patent for Bupivacaine in Back Pain to DURECT
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 13 Dec 2006
Ambit Biosciences Announces Establishment of Clinical Oncology Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2006
EpiCept Announces Relocation of Corporate Headquarters to Tarrytown, New York
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
New Evoltra(R) Data Shows Impressive Response and Survival Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
INNOVIVE Pharmaceuticals Acquires Exclusive North American Rights to Tamibarotene, a Treatment for Acute Promyelocytic Leukemia; Company to Initiate Pivotal Study in 2007
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Dec 2006
Ambit Biosciences Appoints Kerry Kelly, J.D., as Vice President and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin(R) by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Nov 2006
EpiCept Announces Successful Validation of Marketing Authorization Application for Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2006
EpiCept Regains North American Rights to LidoPAIN(R) SP
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 Oct 2006
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Oct 2006
EpiCept Files for Marketing Approval of Ceplene(TM) in European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Oct 2006
EpiCept Resolves All Remaining Litigation Against Maxim Pharmaceuticals
Biopharmaceuticals Litigation
 HSMN NewsFeed - 2 Oct 2006
EpiCept Announces IND Filing of Novel Compound with Potent Apoptotic and Tumor Selective Vascular Disruptive Activity for Treatment of Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Sep 2006
Xenomics Announces Development of Test for the Genetic Marker for Acute Myeloid Leukemia (AML)
Diagnostics Oncology
 HSMN NewsFeed - 19 Sep 2006
Lorus Therapeutics announces the appointment of a new President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2006
Combination of High Dose QUADRAMET(R) and Chemotherapy Shows Promise for Treatment of High-Risk Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2006
EpiCept Announces Results of European Phase III Trial for LidoPAIN(R) SP
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 10 Aug 2006
Dacogen(TM) (Decitabine) for Injection Receives U.S. Orphan Drug Designation for Patients with AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Aug 2006
ChemGenex Announces Publication Of Two New Clinical Studies Supporting Expanded Opportunity For Ceflatonin(R) Beyond CML To Other Leukemias
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2006
Dacogen(TM) (Decitabine) For Injection Receives European Orphan Drug Designation for Patients With AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2006
MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson & Johnson Company, for Dacogen(TM) (decitabine) for Injection
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Jun 2006
Celator Pharmaceuticals Appoints Industry Veteran Felix Botelho as Head of Commercial Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2006
Bioenvision's Evoltra(TM) (clofarabine) Prolongs Survival in Elderly AML Patients with Adverse Cytogenetics
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2006
Results of a Meta-Analysis Show Benefits of Taxotere(R) (Docetaxel) Regimens in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 11 May 2006
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome(R) from Gilead Sciences
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 May 2006
U.S. FDA Approves Dacogen(TM) (Decitabine) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Apr 2006
Bioenvision's Evoltra(R) Achieves High Response Rates in Adult AML
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2006
Cephalon Oncology Compound Lestaurtinib (CEP-701) Granted Orphan Drug Designation for Acute Myeloid Leukemia
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 31 Mar 2006
EpiCept Announces Publication of Phase III Ceplene(TM) Study Results for Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2006
TAXOTERE(R) Receives U.S. FDA Approval For Use In Advanced Stomach Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Mar 2006
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2006
Genasense(R) New Drug Application Accepted for Review by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jan 2006
Ambit Biosciences Appoints Donald R. Myll Senior Vice President Commercial Operations and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Jan 2006
Vion Pharmaceuticals Receives Orphan Drug Designation for Cloretazine(R) in Europe for Treatment of Acute Myeloid Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Jan 2006
Meghan Fitzgerald Joins Vion's Senior Management Team
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 120

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 120 additional stories matching:
Acute Myeloid Leukemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.